- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07291232
성인 비만 환자에서 ABBV-295 피하 주사의 부작용 및 약동학을 평가하는 연구
비만이 있는 성인 대상자에서 ABBV-295의 다중 피하 투여량의 안전성, 내약성, 약동학, 면역원성 및 약력학을 평가하기 위한 1b상 임상시험
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
연구 개요
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
California
-
Anaheim, California, 미국, 92801
- CenExel Act- Anaheim Clinical Trials /ID# 283200
-
-
Illinois
-
Grayslake, Illinois, 미국, 60030
- Acpru /Id# 278624
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- BMI ≥ 30.0 to ≤ 45.0 kg/m2 after rounding to the tenths decimal at Screening (BMI is calculated as weight in kg divided by the square of height measured in meters) with or without weight related stable comorbidities (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).
- A female who is not pregnant or breastfeeding and is not considering becoming pregnant or donating eggs during the study or for approximately 60 days after the last dose of study treatment.
Exclusion Criteria:
- Participant has a self-reported change in body weight ≥ 5% within 3 months prior to Screening.
- HbA1c ≥ 6.5% and/or serum glucose ≥ 126 mg/dL at Screening.
- Participant has taken a medication for the purpose of treating obesity or has been enrolled in an obesity trial within 180 days prior to study treatment administration.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: ABBV-295 or Placebo-Group 1
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
실험적: ABBV-295 or Placebo-Group 2
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
실험적: ABBV-295 or Placebo-Group 3
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
실험적: ABBV-295 or Placebo-Group 3 Extension
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks or 20 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
실험적: ABBV-295 or Placebo-Group 4
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
실험적: ABBV-295 or Placebo-Group 4 Extension
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks or 20 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
실험적: ABBV-295 or Placebo-Group 5
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 20 weeks. |
Subcutaneous Injections Subcutaneous Injections |
|
실험적: ABBV-295 or Placebo-Group 6
Participants will receive subcutaneous doses of ABBV-295 or Placebo for 20 weeks. |
Subcutaneous Injections Subcutaneous Injections |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants with Adverse Events (AEs)
기간: Up to approximately 194 days
|
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. |
Up to approximately 194 days
|
|
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
기간: Up to approximately 194 days
|
Number of participants with abnormal change from baseline in vital sign measurements like heart rate, systolic and diastolic blood pressure will be assessed. |
Up to approximately 194 days
|
|
Number of Participants with Change from Baseline in Electrocardiogram (ECG)
기간: Up to approximately 194 days
|
12-lead resting ECG will be recorded. |
Up to approximately 194 days
|
|
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
기간: Up to approximately 194 days
|
Number of participants with abnormal change in clinical laboratory test results like biochemistry, hematology will be assessed. |
Up to approximately 194 days
|
|
Maximum Observed Plasma Concentration (Cmax) of ABBV-295
기간: Up to approximately 194 days
|
Cmax of ABBV-295 |
Up to approximately 194 days
|
|
Time to Cmax (Tmax) of ABBV-295
기간: Up to approximately 194 days
|
Tmax of ABBV-295 |
Up to approximately 194 days
|
|
Trough plasma concentration (Ctrough) of ABBV-295
기간: Up to approximately 194 days
|
Ctrough of ABBV-295 |
Up to approximately 194 days
|
|
Apparent terminal phase elimination rate constant (BETA) of ABBV-295
기간: Up to approximately 194 days
|
BETA of ABBV-295 |
Up to approximately 194 days
|
|
Terminal phase elimination half-life (t1/2) of ABBV-295
기간: Up to approximately 194 days
|
t1/2 of ABBV-295 |
Up to approximately 194 days
|
|
Area under the plasma concentration-time curve (AUC) of ABBV-295
기간: Up to approximately 194 days
|
AUC of ABBV-295 |
Up to approximately 194 days
|
|
Area under the plasma concentration-time curve over the dosing interval (AUCtau) of ABBV-295
기간: Up to approximately 194 days
|
AUCtau of ABBV-295 |
Up to approximately 194 days
|
|
Dose Normalized Cmax of ABBV-295
기간: Up to approximately 194 days
|
Dose normalized Cmax of ABBV-295 will be assessed. |
Up to approximately 194 days
|
|
Dose Normalized AUC of ABBV-295
기간: Up to approximately 194 days
|
Dose normalized AUC of ABBV-295 will be assessed. |
Up to approximately 194 days
|
|
Incidence of Anti-Drug Antibodies (ADAs)
기간: Up to approximately 194 days
|
Incidence of ADAs will be assessed. |
Up to approximately 194 days
|
|
Percent Change in Body Weight From Baseline
기간: Up to approximately 194 days
|
Percent change in body weight (kg) will be assessed. |
Up to approximately 194 days
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: ABBVIE INC., AbbVie
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- M26-089
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .